Table 2.
Baseline characteristics, by treatment group
| Omega-3 N = 42 n (%) |
Placebo N = 43 n (%) |
|
|---|---|---|
| Age in years (mean ± SD) | 48.9 ± 10.6 | 45.5 ± 10.8 |
| Gender (%) | ||
| Female | 41 (97.6) | 39 (90.7) |
| Male | 1 (2.4) | 4 (9.3) |
| Ethnicity (%) | ||
| Caucasian | 27 (64.3) | 20 (46.5) |
| African-American | 13 (31.0) | 19 (44.2) |
| Asian | 0 (0.0) | 1 (2.3) |
| Other | 2 (4.8) | 3 (7.0) |
| History of smoking (%) | 13 (31.0) | 19 (44.2) |
| Any anti-hypertensive (%) | 30 (71.4) | 22 (51.2) |
| Diabetes (%) | 4 (9.5) | 3 (7.0) |
| Disease activity (mean ± SD) | ||
| SELENA-SLEDAIa | 1.5 ± 2.0 | 1.5 ± 2.5 |
| PGAb | 0.49 ± 0.52 | 0.41 ± 0.49 |
| Systolic BP (mean ± SD) | 119.4 ± 14.6 | 119.4 ± 11.9 |
| Cumulative prednisone dose in last year (mg/d, mean ± SD) |
1.6 ± 2.4 | 3.4 ± 4.5 |
| BMI (mean ± SD) | 28.5 ± 6.0 | 29.0 ± 6.6 |
| BMI (median, IQR) | 27.8 (7.6) | 28.9 (9.8) |
a
SELENA-SLEDAI—SELENA revision of the Systemic Lupus Erythematosus Disease Activity Index
b
PGA—physician global assessment on a 0–3 visual analog scale